BI 3011441
1469-0002
Phase 1 small_molecule completed
Quick answer
BI 3011441 for Solid Tumors, KRAS Mutation is a Phase 1 program (small_molecule) at Boehringer Ingelheim with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim
- Indication
- Solid Tumors, KRAS Mutation
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed